Promentis Pharmaceuticals pulls in $26 mln Series C
Promentis Pharmaceuticals, a biopharmaceutical company focused on treating central nervous disorders, has raised $26 million in Series C funding. OrbiMed, F-Prime Capital Partners and Aisling Capital led the round with participation from other investors that included Black Pearl GmbH and the Golden Angel Network.
30 March 2017•1 min read
